Clinical Trial

Tenofovir Disoproxil Fumarate in the Treatment of Parkinson's Disease

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated February 17, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
To evaluate the efficacy and safety of tenofovir disoproxil fumarate in the treatment of Parkinson's disease. The changes of motor symptoms and the occurrence of adverse reactions in early Parkinson's disease patients who took tenofovir disoproxil fumarate and did not take Tenofovir disoproxil fumarate at different time points were compared.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-04-07; most recent amendment 2025-02-14.
Trial Details
NCT Number NCT06356662
Lead Sponsor The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Conditions Parkinson Disease
Enrollment 60 participants
Start Date 2024-01-23
Primary Completion 2025-12-31 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-02-17